Pfizer

Pfizer's Setback Fuels Surge in M&A Activity Among Obesity Treatment Developers

1 month ago

In a surprising turn of events, Pfizer Inc. reported a setback with its obesity treatment candidate, leading to a significant uptick in interest and market activity among developers in the obesity treatment sector. The pharmaceutical company, which had high hopes pinned on its new drug, announced that further development would be halted due to underwhelming efficacy results in clinical trials. This news has shaken the market, prompting both investors and competitors to reassess their strategies in the race against obesity, a growing health crisis worldwide.

Major Setback for Pfizer: Obesity Pill Development Halted Due to Liver Injury Concerns

1 month ago

In a significant development within the pharmaceutical sector, Pfizer Inc. has announced the abandonment of its obesity treatment pill, a decision driven by alarming reports of liver injuries associated with the medication. This setback marks a considerable shift in the company's strategy to target the growing obesity epidemic, which has seen a dramatic rise in global prevalence in recent years.

Alnylam Secures Expanded Approval for Heart Drug, Paving the Way for Competition with Pfizer

2 months ago

In a significant development within the pharmaceutical industry, Alnylam Pharmaceuticals has received an expanded approval for its heart disease treatment, a move that positions the company squarely in competition with industry giant Pfizer. This latest FDA endorsement is expected to have profound implications for both companies and the market at large, particularly as the demand for innovative cardiovascular therapies continues to rise.

Pfizer Prepares to Divest Final Share of Haleon as Strategic Shift Takes Shape

2 months ago

Pfizer Inc. is making significant moves as it aims to fully divest its stake in Haleon, the consumer healthcare business it previously shared with GlaxoSmithKline (GSK). The pharmaceutical giant has announced plans to execute a final sale of its shareholding in Haleon, a move that signifies a strategic shift as Pfizer refocuses on enhancing its core pharmaceutical and vaccine operations.

Pfizer's Vepdegestrant Shows Mixed Results in Crucial Breast Cancer Trial

2 months ago

Pfizer Inc. has recently announced the results of its key clinical trial for Vepdegestrant, a drug aimed at treating hormone receptor-positive breast cancer. The findings indicate a mixed response in the effectiveness of the medication, presenting both potential and limits in its application for patients battling this challenging form of cancer.

Pfizer Faces Potential European Tariffs, CEO Bourla Warns

3 months ago

In a startling revelation, Pfizer's Chief Executive Officer Albert Bourla expressed concerns regarding the company's vulnerability to potential tariffs imposed by European nations. This declaration comes in the wake of ongoing negotiations and shifts within global trade frameworks, which may affect the pharmaceutical giant’s operations and profitability in the continent.

New Build: $135 Million Financing Secured for Transformation of Former Pfizer Headquarters in NYC

4 months ago

A significant development is underway in New York City as plans evolve to convert the former Pfizer headquarters into a mixed-use space. The ambitious project has recently received a substantial boost in funding, securing a loan of $135 million to help facilitate this transformation.

Sangamo Therapeutics Faces Deplorable Stock Plunge Following Pfizer's Withdrawal from Hemophilia Treatment Deal

5 months ago

Sangamo Therapeutics, a company specializing in gene therapy and related innovations, witnessed a catastrophic decline in its stock value after pharmaceutical giant Pfizer decided to terminate their partnership regarding a hemophilia treatment. This abrupt end to the collaboration has sent shockwaves through the markets and raised numerous questions about the future capabilities and financial health of Sangamo.

Pfizer Appoints New Chief Science Officer, Boosting Leadership in Oncology

6 months ago

Pfizer, one of the world’s leading biopharmaceutical companies, has announced a significant leadership change by appointing Dr. Angela Boshoff as its new Chief Science Officer (CSO). This move is notable, coming on the heels of her previous role leading the oncology division within the company, where she was instrumental in advancing Pfizer’s portfolio of cancer therapies.

Activist Investor Starboard Value Makes a Bold Move with a $1 Billion Stake in Pharmaceutical Giant Pfizer

8 months ago

In a significant financial maneuver, Starboard Value LP, a prominent activist investment firm, has acquired a substantial $1 billion stake in the global pharmaceutical behemoth Pfizer Inc. This strategic investment marks an assertive push by Starboard into the healthcare sector, aiming to influence the company's direction and potentially unlock shareholder value.